Stocks
Intelligent OutlookGILD-
Intelligent Outlook
GILD-
Prev Close-
50D MA-
200D MA-
52W High-
Live Price
GILD 24H Rolling
0.000.00%0.00
Rolling: Last 24h | 5m
GILD
Asset Information
Company Profile
Company:GILD
Sector:Biotechnology
Industry:Biotechnology
Country:US
Employees:17,600
IPO Date:1992-01-22
Website:www.gilead.com/
Technicals & Growth
Market Cap:$152.10B
Shares O/S:1,240,810,000
52W High:$124.61
52W Low:$86.08
50D MA:$116.01
200D MA:$110.13
Financial Ratios
P/E Ratio:14.97
EPS:$8.19
Profit Margin:28.90%
ROE (TTM):37.62%
ROA (TTM):14.42%
Div. Per Share:$3.14
GILD
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Loading chart library...
Financial Data (Macrotrends)
Historical Data
Loading...